This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of the Effectiveness of Passive Immunotherapy in HIV-Infected Patients Who Are in Virologic Failure

This study has suspended participant recruitment.
(low recruitment)
Information provided by:
Hospital Clinic of Barcelona Identifier:
First received: July 17, 2006
Last updated: March 28, 2008
Last verified: March 2008
To study the effect of passive immunotherapy (PIT) over the HIV-viral load and the CD4 T+-cell counts in patients who have failed to respond to three different Highly-Active Antiretroviral Therapy (HAART), and who have at the moment less than 100 CD4+-T cells/ml and a viral load over 20,000 copies/ml.

Condition Intervention Phase
HIV Infection Procedure: Plasma infusion Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Passive Immunotherapy in HIV-Infected Patients Who Fail to Respond to Multiple Highly Active Antiretroviral Treatment. Randomized Study in Two Phases.

Resource links provided by NLM:

Further study details as provided by Hospital Clinic of Barcelona:

Primary Outcome Measures:
  • Lowering of plasma viral load after the first plasma infusion
  • Lowering of plasma viral load after a year

Secondary Outcome Measures:
  • Elevation of CD4 T cell count
  • Negativation of p24 HIV antigen
  • HIV RNA mutations conferring resistance to HAART
  • Development of C-events
  • Dead
  • Toxicity
  • Accomplishment

Estimated Enrollment: 30
Study Start Date: October 2006
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV-1 infected patients (CDC C category) confirmed by a Western-blot
  • CD4 T cell count under 100/ml form 6 months before the inclusion, and who have never been over 600 CD4 T cells/ml in the last 6 months, even if they have been receiving HAART.
  • The patients have received at least 3 different HAART regimens, and they have failed to respond (define failure: CD4 T cell count under 100/ml and plasma viral load over 20,000 copies/ml).
  • Plasma viral load over 20,000 copies/ml during at least 6 months.
  • Written informed consent
  • 18 years old or older

Exclusion Criteria:

  • Asymptomatic patients who fill the A category of the CDC (1993)
  • Younger than 18 years old
  • Who are not expected to accomplish the treatment or the follow up visits
  • Pregnancy, breast-feeding women, or women who want to get pregnant
  • Denied consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00353327

Hospital Clínic Barcelona
Barcelona, Spain, 08036
Sponsors and Collaborators
Hospital Clinic of Barcelona
Principal Investigator: Felipe Garcia, MD, PhD Hospital Clinic of Barcelona
  More Information

Responsible Party: Felipe García, Hospital Clinic Identifier: NCT00353327     History of Changes
Other Study ID Numbers: PIT-01
Study First Received: July 17, 2006
Last Updated: March 28, 2008

Keywords provided by Hospital Clinic of Barcelona:
Passive immunotherapy

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases processed this record on September 19, 2017